Volume 17 Issue 3
Aug.  2022
Turn off MathJax
Article Contents
LIU Shu-rong, ZHANG Xiao-hua, QIAN Feng, . Clinical study of Qiangxinkang granule in the treatment of chronic heart failure[J]. Chinese Journal of General Practice, 2019, 17(3): 364-366. doi: 10.16766/j.cnki.issn.1674-4152.000682
Citation: LIU Shu-rong, ZHANG Xiao-hua, QIAN Feng, . Clinical study of Qiangxinkang granule in the treatment of chronic heart failure[J]. Chinese Journal of General Practice, 2019, 17(3): 364-366. doi: 10.16766/j.cnki.issn.1674-4152.000682

Clinical study of Qiangxinkang granule in the treatment of chronic heart failure

doi: 10.16766/j.cnki.issn.1674-4152.000682
  • Received Date: 2018-01-20
  • Objective To evaluate the clinical efficacy of Qiangxinkang Granule in the treatment of chronic heart failure and provide clinical case data for the development of hospital preparations. Methods Total 200 patients with chronic heart failure were randomly divided into treatment group and control group, with 100 cases in each group. On the basis of western medicine treatment, the treatment group received additional Qiangxinkang granules (1 bag, 10 g), twice a day, for 8 weeks. Before and after the treatment, the 6-minute walking distance, plasma NT-proBNP concentration, TCM syndromes score were observed and the clinical efficacy was evaluated. Results The curative effect of TCM syndrome: by rank sum test, the treatment group was superior to the control group, but there was no statistical difference between the two groups (P>0.05). In 6-minute walking distance, the walking distance after the treatment in both groups was prolonged. In the treatment group, it was improved significantly (P<0.05), however in the control group, it was not significant (P>0.05). After the treatment, there was significant difference between the treatment group and the control group (P<0.05). The level of plasma NT-proBNP after the treatment decreased in both group to varying degrees, significantly in the treatment group (P<0.05). After the treatment, there was no statistical difference in the level of plasma NT-proBNP between the two groups (P>0.05). Conclusion For patients with chronic heart failure, the addition of Qiangxinkang granule to the standardized treatment of western medicine can alleviate the clinical symptoms of patients with heart failure, increase the walking distance of patients with heart failure for 6 minutes, reduce the concentration of NT-proBNP in plasma, and improve the quality of life of patients. The result provides a reference for the research and development of hospital preparations, and worth to be widely used in clinic.

     

  • loading
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (115) PDF downloads(0) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return